Clinical trial

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18]…

NCT00325130 · Merck Sharp & Dohme LLC, Industry · Completed

Key facts

NCT number NCT00325130
Title Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
Official title An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V501 Given Concomitantly With Menactra™ and ADACEL™ in Healthy Adolescents 11-17 Years of Age
Lead sponsor Merck Sharp & Dohme LLC, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough, Meningitis
Intervention type Biological
Interventions Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine, Comparator: Menactra™ (Concomitant), Comparator: Adacel™ (Concomitant), Comparator: Menactra™ (Non-concomitant), Comparator: Adacel™
Enrollment 1,042
Start date Apr 1, 2006
Primary completion Apr 1, 2007
Completion Apr 1, 2007
First posted May 12, 2006
Last update posted Mar 12, 2015

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies